CHILDREN AGED 1-11 YEARS

Differences in the number of days with ≥1 sign or symptom of EoE via LSM change in PESQ-C were observed at Week 16.^3,a

• EoE KIDS-Part A: -0.21 reduction (~2.9 fewer days)  from baseline with DUPIXENT (n=32) vs -0.16 reduction (~2.2 fewer days) with placebo (n=29)

A decrease in the number of days with ≥1 sign or symptom of EoE via LSM change in PESQ-C were observed at Week 52.^3,a

• EoE KIDS-Part B: -0.26 reduction (~3.6 fewer days) from baseline with DUPIXENT (n=22) and -0.39 reduction (~5.5 fewer days) from baseline after switching to DUPIXENT from placebo at Week 16 (n=7)

Definitive conclusions cannot be made. Numerical improvements were observed at Week 16 and maintained for 52 weeks. Results are descriptive at Week 52 due to limitations associated with extended active treatment design including lack of comparator arm and decreasing sample size.³

^aSecondary endpoint at Weeks 16 and 52.³

VIEW THE CLINICAL RESULTS IN CHILDREN (1-11 YEARS)